Loading
EIK1005 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for colorectal cancer, endometrial cancer.
EIK1005 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Eikon Therapeutics, in colorectal cancer, endometrial cancer. Described in the registry record as a eik1005 is a selective inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
Described in the registry record as a eik1005 is a selective inhibitor; the trial entries below carry the sponsor's wording. Connects to WRN helicase (MSI-high cancers).
1.EIK1005 slips into a pocket on WRN helicase (MSI-high cancers).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"EIK1005" OR ABSTRACT:"EIK1005") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EIK1005, not a curated reading list.
Shares Eikon Therapeutics and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Endometrial cancer and the tags pipeline, registry-only.
Shares Endometrial cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.
Shares Colorectal cancer and the tags pipeline, registry-only.